Phase 3 FIRST Trial in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Subgroup Analysis of Patients From Canada and the United States

被引：0

作者：

Belch, Andrew ^{[1
]}

Bahlis, Nizar J. ^{[2
]}

White, Darrell ^{[3
,4
]}

Cheung, Matthew ^{[5
]}

Chen, Christine ^{[6
]}

Shustik, Chaim ^{[7
]}

Song, Kevin ^{[8
]}

Tosikyan, Axel ^{[9
]}

Dispenzieri, Angela ^{[10
]}

Anderson, Kenneth C. ^{[11
]}

Kotey, Stanley ^{[12
]}

Brown, Diane ^{[13
]}

Robinson, Suzanne ^{[12
]}

Srinivasan, Shankar ^{[12
]}

Facon, Thierry ^{[14
]}

机构：

[1] Cross Canc Inst, Edmonton, AB, Canada

[2] Tom Baker Canc Clin, Calgary, AB, Canada

[3] Dalhousie Univ, Halifax, NS, Canada

[4] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[5] Odette Canc Ctr, Toronto, ON, Canada

[6] Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

[8] Vancouver Gen Hosp, Leukemia BMT Program BC Div Hem, Vancouver, BC, Canada

[9] Hop Sacre Coeur Montreal, Montreal, PQ, Canada

[10] Mayo Clin, Rochester, MN USA

[11] Dana Farber Canc Inst, Boston, MA 02115 USA

[12] Celgene Corp, Summit, NJ USA

[13] Celgene Corp, Mississauga, ON, Canada

[14] Hop Claude Huriez, Serv Malad Sang, Lille, France

来源：

关键词：

Lenalidomide; newly diagnosed MM; Transplant-ineligible;

D O I：

10.1016/j.clml.2019.09.374

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

sp-048

引用

页码：E225 / E225

页数：1